Company Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna’s PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial.
The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial.
The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications.
Immatics N.V. is headquartered in Tübingen, Germany.
Contact Details
Address: Paul-Ehrlich-Strasse 15-19 Tübingen, 72076 Germany | |
| Phone | 49 7071 5397 0 |
| Website | immatics.com |
Stock Details
| Ticker Symbol | IMTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 1809196 |
| CUSIP Number | N44445109 |
| ISIN Number | NL0015285941 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Harpreet Singh Ph.D. | Chief Executive Officer, MD, Member of Management Board and Executive Director |
| Dr. Venkat Ramanan Ph.D. | Chief Financial Officer |
| Amie Krause | Chief People Officer |
| Dr. Hans-Georg Rammensee Ph.D. | Co-Founder and Member of the Scientific Advisory Board |
| Dr. Toni Weinschenk Ph.D. | Co-Founder and Chief Innovation Officer |
| Steffen Walter Ph.D. | Chief Operations Officer |
| Ephraim Hofsäß M.Sc. | Vice President of SEC Reporting and Accounting |
| Edward A. Sturchio | General Counsel and Secretary |
| Lauren Schroeder | Vice President of Marketing |
| Dr. Carsten Reinhardt M.D., Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 5, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 5, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | 6-K | Report of foreign issuer |
| Dec 11, 2025 | 6-K | Report of foreign issuer |
| Dec 8, 2025 | 6-K | Report of foreign issuer |
| Dec 5, 2025 | 424B5 | Filing |
| Dec 5, 2025 | 424B5 | Filing |
| Nov 17, 2025 | 6-K | Report of foreign issuer |